Session » Antiphospholipid Syndrome - Poster II

Date: Tuesday, November 15, 2016

Time: 9:00AM-11:00AM

Meeting: 2016 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2087

A Type I Interferon Signature in Monocytes and Decreased Levels of Circulating Plasmacytoid Dendritic Cells in Patients with Primary Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 2091

Antiphospholipid Syndrome Patients’ Time within Therapeutic Range of International Normalized Ratio (INR)

9:00AM-11:00AM: Abstract Number: 2093

Association of Conventional Risk Factors and Antiphospholipid Antibodies to Thrombosis in Patients with Autoimmune Diseases: Lessons Learned from a Year-Long Systematic Assessment

9:00AM-11:00AM: Abstract Number: 2095

Autoantibodies Against High Density Lipoprotein-Associated Proteins Are Related to Elevated Oxidized Low Density Lipoprotein Levels in Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 2097

Cardiolipin-Producing Candidate Commensals in the Gut Microbiome of Antiphospholipid Syndrome Patients

9:00AM-11:00AM: Abstract Number: 2094

Complement Activation in Antiphospholipid Syndrome Due to the Multi-Activated Pathways of the Complement System

9:00AM-11:00AM: Abstract Number: 2089

Deviation of T and B Cell Subset and Its Association with Single Nucleotide Polymorphisms in Patients with Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 2086

Hexagonal Phase Phospholipid Neutralization Assay Is the Most Sensitive but Least Specific Among Nine Tests for Detecting APS in SLE or Non-SLE Patients

9:00AM-11:00AM: Abstract Number: 2090

Investigating the Genetic Variations of Antiphospholipid Syndrome By High-Throughput Exome Sequencing

9:00AM-11:00AM: Abstract Number: 2099

Micrornas As Potential Modulators of Atherothrombosis in Antiphospholipid Syndrome

9:00AM-11:00AM: Abstract Number: 2098

Non-Criteria Anti-Phospholipid Antibodies in SLE Patients

9:00AM-11:00AM: Abstract Number: 2100

Pharmaceutical Disruption of B2GPI CXCL4 Complex Using Computationally Designed Oligopeptides

9:00AM-11:00AM: Abstract Number: 2092

Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Is Elevated in Patients with Thrombotic Primary Antiphospholipid Syndrome.

9:00AM-11:00AM: Abstract Number: 2088

Rituximab Use in Pediatric Lupus Anticoagulant Hypoprothrombinemia Syndrome – Report of Three Cases and Review of the Literature

9:00AM-11:00AM: Abstract Number: 2101

the Association Between ABO Blood Types and Venous Thromboembolism in Individuals with a Positive Antiphospholipid Antibody Profile Is Varied By Sex

9:00AM-11:00AM: Abstract Number: 2102

the Prevalence and Associations of IgG/a/M ANTI-β2GPI and ANTI-Domain I Antibodies in an Antiphospholipid Syndrome (APS) Cohort of Patients from Turkey

9:00AM-11:00AM: Abstract Number: 2096

Venous Antiphospholipid Syndrome: Is the Unprovoked Nature of the 1st Thrombosis Associated with Clinical or Biological Features?

« View all sessions from this meeting